Supplementary material

Structural characterization of compounds in peak 1

Figure S1. Chromatogram (trace at 210 nm) of peak 1.





Figure S2. HRMS spectra of compound 1 (3.55 min) and secondary compound 1' (3.90 min) in peak 1.






Figure S3. UV-vis (DAD) spectra of compound 1 (3.55 min) and secondary compound 1' (3.90 min) in peak 1.

Figure S4. ¹H NMR spectrum of peak 1 (DMSO- d_6 , 500 MHz).




Figure S5. HSQC spectrum of peak 1.




Figure S6. Key HMBC correlations for main compound 1 in peak 1, which connect the *N*-acetylcysteine moiety to the thiazoline heterocycle







Figure S7. Key NOESY correlation for main compound 1 in peak 1, which determines the relative configuration of the thiazoline heterocycle.







Structural characterization of compounds in peak 2





Figure S9. Chromatogram (trace at 210 nm) of peak 2.

Figure S10. HRMS spectra of compound 2 (3.57 min) and secondary compound 2' (3.90 min) in peak 2.









Figure S11. UV-vis (DAD) spectra of compound 2 (3.57 min) and secondary compound 2' (3.91 min) in peak 2.

Figure S12. ¹H NMR spectrum of peak 2 (DMSO-*d*₆, 500 MHz).







Structural characterization of compounds in peak 3

Figure S14. Chromatogram (trace at 210 nm) of peak 3.






Figure S15. HRMS spectra of compound 3 (3.77 min) and secondary compound 3' (4.07 min) in peak 3.








Figure S17. ¹H NMR spectrum of peak **3** (DMSO- d_6 , 500 MHz).





Figure S18. HSQC spectrum of peak 3.



Structural characterization of compounds in peak 4

Figure S19. Chromatogram (trace at 210 nm) of peak 4.




Figure S20. HRMS spectra of compound 4 (3.81 min) and secondary compound 4' (4.09 min) in peak 4.




Figure S21. UV-vis (DAD) spectra of compound 4 (3.81 min) and secondary compound 4' (4.09 min) in peak 4.




Figure S22. ¹H NMR spectrum of peak 4 (DMSO- d_6 , 500 MHz).




Figure S23. HSQC spectrum of peak 4.




Figure S24. UPLC chromatograms, monitored at 238 nm, of mutant *S. albus* B29 grown in R5A liquid medium and fed with 50 μ g mL⁻¹ of compound **1**.




Figure S25. UPLC chromatograms, monitored at 238 nm, of mutant *S. albus* B29 grown in R5A liquid medium and fed with 50 μ g mL⁻¹ of compound **2**.




Figure S26. UPLC chromatograms, monitored at 238 nm, of mutant *S. albus* B29 grown in R5A liquid medium and fed with 50 μ g mL⁻¹ of compound **4**.




Figure S27. UPLC chromatograms, monitored at 238 nm, of mutant *S. albus* B29 grown in R5A liquid medium and fed with 50 μ g mL⁻¹ of paulomycin B (6) that is transformed into paulomenol B (8) and compound (2).




Figure S28. UPLC chromatograms, monitored at 238 nm, of mutant *S. albus* B29 grown in R5A liquid medium and fed with 50 μ g mL⁻¹ of paulomycin A (5) that is transformed into paulomenol A (7) and compound (3).

